Sigma Genetics is building the next-generation platform for intracellular delivery, enabling scalable, high-efficiency cell engineering across therapeutics and biomanufacturing. Our magnetoporation technology unlocks new possibilities in immunotherapies, blood products, and synthetic biology, paving the way for faster, safer, and more cost-effective cell-based solutions. We aim to become the foundational delivery engine powering the future of cell and gene therapy.
The successful intracellular delivery of molecules and genes is a critical challenge in the production of cellular products and gene-modified cell therapies. Current solutions, such as viral transduction and electroporation, often damage cells, which can reduce therapeutic efficacy, cell viability, and hinder scalability. Overcoming these limitations could significantly accelerate the development of cellular products, genetic research, and drug discovery. Moreover, advancing this technique for direct vein-to-vein applications could facilitate the commercialization and access to the most advanced healthcare products and therapies.
$3.6M raised to date: $1.89M from venture and angel investors, plus $1.73M in non-dilutive grants, including from the Andy Hill CARE Fund and U.S. DoD (AFWERX SBIR).
Flagship Magnetoporator™ platform enables scalable, non-viral intracellular delivery with high efficiency and viability across primary human cells, stem cells, and cell lines.
Strategic collaborations:
Seattle Children’s Research Institute / National Resilience (CAR-T manufacturing)
USAF 59th Medical Wing & Bloodworks Research Institute (lyophilized RBCs for trauma and oncology)
Intellectual property: 1 granted U.S. & AU patent (EU pending), 1 international provisional filed.
Advanced prototype & commercialization: >15 device iterations completed; supporting research and clinical-ready cGMP versions.
Active pipeline: Applications in CAR-T therapy, lyophilized RBCs, and engineered cellular products.
